As Covid rises again, killing about 1,500 Americans each week, medical researchers are trying to understand why so few people are taking Paxlovid, a medicine that is stunningly effective in preventing severe illness and death from the disease.
Due to its rapid growth and potential to add to the respiratory virus burden in Northern Hemisphere countries, the World Health Organization (WHO) today designated JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest.
Over the past month, the proportion of JN.1 viruses has rapidly increased, rising from 3.3% in early November to 27.1% by early December. Countries reporting the highest proportions include France, the United States, Singapore, Canada, and the United Kingdom.
Recent Comments